Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments (TA1008)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 September 2024
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency (TA914)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 September 2023
Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care (DG56)Product type:GuidanceProgramme:Diagnostics guidancePublished: 24 August 2023
Regorafenib for previously treated metastatic colorectal cancer (TA866)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 February 2023
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA716)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 July 2021
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA709)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 June 2021
Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer (TA668)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 January 2021
Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 May 2020
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 25 September 2017Published: 29 March 2017
Virtual chromoendoscopy to assess colorectal polyps during colonoscopy (DG28)Product type:GuidanceProgramme:Diagnostics guidancePublished: 10 May 2017
Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) (TA240)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 29 March 2017Published: 14 December 2011
Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27)Product type:GuidanceProgramme:Diagnostics guidancePublished: 22 February 2017
Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 August 2016
Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) (TA334)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 February 2015
Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (DG16)Product type:GuidanceProgramme:Diagnostics guidancePublished: 10 December 2014
Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 March 2014
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 January 2012
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 1 January 2012Published: 24 January 2007
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 December 2010
Laparoscopic surgery for colorectal cancer (TA105)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 August 2006
Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer (TA100)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 April 2006
Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer (TA61)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 May 2003